Driving Change: Using Emergency Department Data To Reduce Alcohol-related Harm
Funder
National Health and Medical Research Council
Funding Amount
$1,468,026.00
Summary
The proposed project is a system change within partner emergency departments, providing them the information and tools to act on both risky alcohol consumption in individual patients and the sources of alcohol in the community which cause the harm they experience. Most importantly, the proposed public health interventions act as a tool for emergency departments to regularly raise awareness with the public and policymakers regarding the impact of alcohol on patients, clinicians and hospitals.
Unravelling The Mechanism Of MHC Class-I Associated Drug Hypersensitivities
Funder
National Health and Medical Research Council
Funding Amount
$566,308.00
Summary
Some drugs cause adverse reactions that are life threatening. We think these reactions are mediated by killer T cells as they are genetically controlled by immune response genes that normally guide immunity to microbes. We will study immune reactions to the drug abacavir, used to treat HIV (AIDS); allopurinol used to prevent gout and carbamazepine, used to treat epilepsy. The study may also help devise better treatments for patients who experience severe forms of these reactions.
Aboriginal and non-Aboriginal sex-offenders in Australia: Assessing risk for practice and policy. A key priority of Australian governments is to improve community safety through reducing the risk of sex offenders re-offending after release from prison. This project will assess the validity of tools used to predict the risk of sexual offender recidivism and identify alternate risk assessment tools for Indigenous and non-Indigenous sex offenders.
DYRK1A As A Novel Target For Glioblastoma Therapies
Funder
National Health and Medical Research Council
Funding Amount
$620,294.00
Summary
Glioblastoma is a form of brain cancer that is currently incurable. We have discovered that switching-off an enzyme called DYRK1A (using ‘DYRK1A inhibitors’) kills glioblastoma cells. This therapeutic advantage is even greater when combined with drugs approved for other cancers. This project will develop new DYRK1A inhibitors and examine a novel combination treatment for glioblastoma patients. This could initiate a novel therapy that could significantly extend patients’ lives.
Centre Of Research Excellence In Cardiovascular Outcomes Improvement
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
Quality, safety and the effectiveness of providing prevention and treatments to those with cardiovascular disease is the focus of research of the CRE in Cardiovascular Outcomes Improvement. Utilizing data derived from clinical registries and large patient databases of patients receiving various treatments for heart problems, we will investigate what factors are important in delivering cost-effective favorable outcomes. The centre will train future leaders in cardiovascular research focusing on
Eliminating Hepatitis C Transmission By Enhancing Hepatitis C Care And Treatment In Primary Health Care Settings.
Funder
National Health and Medical Research Council
Funding Amount
$1,221,831.00
Summary
In developed countries, people who inject drugs (PWID) are the group at greatest risk of hepatitis C (HCV) infection but few PWID receive HCV treatment. With the advent of highly effective non-interferon based treatments HCV elimination, although ambitious, is now being seriously considered globally. This partnership grant will explore the feasibility of eliminating HCV transmission by enhancing HCV care and treatment for PWID in primary health care settings.
Towards A National Sports Safety Strategy - Addressing Facilitators And Barriers Towards Safety Guideline Uptake.
Funder
National Health and Medical Research Council
Funding Amount
$965,834.00
Summary
Most sports injury prevention evidence is yet to be translated from professional to community sports settings. Using community-based Australian football clubs, this project will develop and evaluate the strategic implementation of an evidence-based sports safety package. This will provide important information about how to best support community sports clubs to ensure evidence-based safety programs are translated into sustainable policies and practice and public health benefits are maximised
Preclinical Development Of A Therapeutic Anticancer Antibody To C-Met
Funder
National Health and Medical Research Council
Funding Amount
$435,530.00
Summary
Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.
Understanding The Acute And Cumulative Metabolic Effects Of Prolonged Sitting In Adults
Funder
National Health and Medical Research Council
Funding Amount
$416,597.00
Summary
Sedentary behaviour (sitting time) has been linked to an increased risk of chronic illnesses, including type 2 diabetes and obesity, but recent evidence suggests that light-intensity activity (non-exercise activities of daily living) is associated with reduced risk. These studies will examine whether breaking up sitting time with frequent short periods of activity can overcome the negative effects of prolonged sitting on blood glucose and blood fats in overweight older adults.
QUality Improvement In Primary Care To Prevent Hospitalisations And Improve Effectiveness And Efficiency Of Care For People Living With Heart Disease (QUEL)
Funder
National Health and Medical Research Council
Funding Amount
$828,305.00
Summary
Heart disease accounts for a great number of deaths and admissions to hospital. We aim to improve ongoing prevention for people with heart disease by supporting general practices to use their data and provide more systematic care. We propose a randomised trial to determine whether a practice level strategy reduces cardiovascular events and hospitalisations and saves money. The research will directly inform government decision-making and policy regarding primary care incentive payment programs.